Impact of HER2 low status on genomic signatures in triple negative breast cancer (TNBC)

被引：0
|
作者：
Taylor, Melissa
Reddy, Shilpa
Kumar, Prashanth Ashok
Hariri, Dana
Sokol, Ethan
Sivakumar, Smruthy
Quintanilha, Julia
Pavlick, Dean
Levy, Mia Alyce
Ross, Jeffrey S.
Lustberg, Maryam B.
机构：
[1] Yale New Haven Hosp, New Haven, CT USA
[2] Upstate Univ Hosp, Syracuse, NY USA
[3] SUNY Upstate Univ Hosp, Syracuse, NY USA
[4] Fdn Med Inc, Cambridge, MA USA
[5] Fdn Med Inc, Boston, MA USA
[6] Fdn Med, Cambridge, MA USA
[7] Smilow Canc Hosp, Yale Canc Ctr, New Haven, CT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1092
引用
收藏
页数：1
相关论文
共 50 条
  • [31] The impact of carboplatin on pathologic complete response and survival based on HER2 low and HER2 zero status in triple negative breast cancer patients receiving neoadjuvant chemotherapy: a multicenter real-world analysis
    Sedat Yıldırım
    Tugba Başoğlu
    Akif Doğan
    Goncagul Akdağ
    Oguzcan Kınıkoğlu
    Alper Topal
    Ozkan Alan
    Ali Alper Solmaz
    Mustafa Gürbüz
    Timucin Çil
    Rumeysa Çolak
    Mesut Yılmaz
    Ali Kalem
    Nadiye Sever
    Nargiz Majıdova
    Kubilay Karakoyun
    Serhat Sekmek
    Omer Saçlı
    Melike Ozcelık
    Deniz Işık
    Heves Surmeli
    Ozlem Nuray Sever
    Hatice Odabas
    Mahmut Emre Yıldırım
    Nedim Turan
    BMC Cancer, 25 (1)
  • [32] Reassessment of HER2 status in HER2 negative or HER2 unknown breast cancer patients with recurrent metastatic disease by analyzing serum HER2 and HER2 status of circulating tumor cells.
    Fehm, T.
    Lane, N.
    Solomayer, E.
    Wallwiener, D.
    Uhr, J.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S40 - S40
  • [33] Low HER2 expression is a predictor of poor prognosis in stage I triple-negative breast cancer
    Sanomachi, Tomomi
    Okuma, Hitomi Sumiyoshi
    Kitadai, Rui
    Kawachi, Asuka
    Yazaki, Shu
    Tokura, Momoko
    Arakaki, Motoko
    Saito, Ayumi
    Kita, Shosuke
    Yamamoto, Kasumi
    Maejima, Aiko
    Kojima, Yuki
    Nishikawa, Tadaaki
    Sudo, Kazuki
    Shimoi, Tatsunori
    Noguchi, Emi
    Fujiwara, Yasuhiro
    Sugino, Hirokazu
    Shiino, Sho
    Suto, Akihiko
    Yoshida, Masayuki
    Yonemori, Kan
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [34] Neoadjuvant therapy in patients with triple negative and HER2 positive early breast cancer
    Harbeck, N.
    BREAST, 2017, 32 : S18 - S18
  • [35] Impact of neoadjuvant HER2-directed therapy on HER2 status in breast cancer
    Manguso, Nicholas
    Johnson, Jeffrey
    Basho, Reva Kakkar
    McArthur, Heather L.
    Tanaka, Hisashi
    Giuliano, Armando E.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [36] Prognostic factors in nonmetastatic HER2 'low' & HER2 'negative' breast cancer: Single institute experience
    Turkel, A.
    Dogan, M.
    Sertesen, E.
    Karacin, C.
    Irkkan, S. C.
    Ates, O.
    ANNALS OF ONCOLOGY, 2023, 34 : S299 - S300
  • [37] BASELINE PRESENTATION OF TRIPLE NEGATIVE BREAST CANCER (TNBC) AND HER2+/NEU BREAST CANCER AT A CENTRE IN SOUTH INDIA
    Narang, N. Raizada
    B, M. K.
    Thomas, T.
    Bs, A. Kumar
    ANNALS OF ONCOLOGY, 2010, 21 : 116 - 116
  • [38] HER2 status in bilateral breast cancer
    Crowe, Joseph P.
    Patrick, Rebecca J.
    Rybicki, Lisa A.
    Budd, G. Thomas
    Escobar, Pedro F.
    Tubbs, Raymond R.
    Hicks, David G.
    INTERNATIONAL JOURNAL OF FERTILITY AND WOMENS MEDICINE, 2006, 51 (05) : 219 - 223
  • [39] Circular HER2 RNA positive triple negative breast cancer is sensitive to Pertuzumab
    Jie Li
    Maoguang Ma
    Xuesong Yang
    Maolei Zhang
    Jingyan Luo
    Huangkai Zhou
    Nunu Huang
    Feizhe Xiao
    Bingquan Lai
    Weiming Lv
    Nu Zhang
    Molecular Cancer, 19
  • [40] Circular HER2 RNA positive triple negative breast cancer is sensitive to Pertuzumab
    Li, Jie
    Ma, Maoguang
    Yang, Xuesong
    Zhang, Maolei
    Luo, Jingyan
    Zhou, Huangkai
    Huang, Nunu
    Xiao, Feizhe
    Lai, Bingquan
    Lv, Weiming
    Zhang, Nu
    MOLECULAR CANCER, 2020, 19 (01)
12345